指南与共识药物不良反应与药物警戒

欧盟药品风险最小化措施在临床实践指南中实施的挑战:混合方法多案例研究

Challenges in the Implementation of EU Risk Minimisation Measures for Medicinal Products in Clinical Practice Guidelines: Mixed Methods Multi-Case Study.
指南 / 共识 · Drug Saf · 2024-11-21

本研究通过定量分析136份临床实践指南并结合71次访谈,评估欧盟药品风险最小化措施(RMMs)在指南中的纳入情况。结果显示仅25%的指南纳入RMM信息,障碍包括临床医生认知不足、对RMM临床效用期望低及指南与RMM范围不兼容。结论认为需加强监管机构与指南制定者合作以促进实施。

要点

  • 仅25%的相关临床实践指南纳入了风险最小化措施信息。
  • 临床医生对RMM认知低且对其实用性期望不高是主要障碍。
  • 指南制定者与监管机构之间缺乏联系,需加强协作。

核心结论

  • 风险最小化措施信息在相关临床实践指南中的纳入程度非常有限。
  • 该现象可由指南与RMM的特征及国家监管机构与指南制定组织间缺乏联系来解释。
  • 加强利益相关方、国家监管机构与欧洲药品管理局的合作可能促进实施。

研究设计与样本

  • 采用多案例研究设计,对临床实践指南进行定量文件分析并结合对指南发布组织知情者的定性访谈。
  • 研究涵盖五个治疗领域,在六个欧盟成员国(丹麦、希腊、拉脱维亚、荷兰、葡萄牙和斯洛文尼亚)分别进行。
  • 共分析136份临床实践指南,并对71次访谈的逐字稿进行归纳分析。

主要发现

  • 在分析的136份指南中,25%的指南纳入了关于治疗领域的RMM信息。
  • 临床医生尽管知晓RMM所针对的安全问题,但对RMM本身的认知水平低。
  • 临床医生对RMM的临床效用期望低,且不熟悉支持RMM的药物警戒数据。
  • 临床医生认为指南的范围和目的与RMM信息不相兼容。

临床怎么用

  • 临床药师应关注相关指南中RMM信息的缺失,主动补充风险最小化措施的执行要点。
  • 在指南制定或更新过程中,应推动纳入RMM信息并加强与其他利益相关方的沟通。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Risk minimisation measures (RMMs) aim to ensure safe use of medicines, but their implementation in clinical practice is complicated by the diversity of stakeholders whose clinical decision making they seek to inform. Clinical practice guidelines (CPGs) are considered integral in clinical decision making. OBJECTIVES: To determine the extent to which RMMs are included in the relevant CPGs and to describe factors that determine RMM inclusion. METHODS: A multi-case study design using quantitative document analysis of CPGs combined with qualitative interviews with informants from organisations that issue CPGs. Cases from five therapeutic areas (TAs) with a regulatory requirement for further RMMs were studied individually in six EU member states (Denmark, Greece, Latvia, Netherlands, Portugal and Slovenia). Clinical practice guidelines were analysed using pre-defined coding frameworks. Interviewees were sampled purposively for experience and knowledge about CPG development and RMM inclusion. Verbatim interview transcripts were analysed inductively. RESULTS: In total, 136 CPGs were analysed, and RMM information about TAs was included in 25% of CPGs. Based on 71 interviews we found that factors that determine RMM inclusion in CPGs include clinicians' low awareness of RMMs despite awareness of RMMs' safety concern, low expectation of RMMs' clinical utility, and unfamiliarity with pharmacovigilance data supporting RMMs and perceived incompatibility of CPGs' scope and purpose and RMM information. CONCLUSIONS: The inclusion of RMM information in relevant CPGs is remarkably limited. It may be explained by characteristics of CPGs and of RMMs as well as lack of connection between national regulators and organisations and authors developing CPGs. More collaboration between stakeholders, national regulators and the EMA may advance implementation.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Møllebæk M, Gardarsdottir H, Bikou AG, et al. Challenges in the Implementation of EU Risk Minimisation Measures for Medicinal Products in Clinical Practice Guidelines: Mixed Methods Multi-Case Study. Drug Saf. 2024. PMID: 39570566. doi:10.1007/s40264-024-01487-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。